NEW YORK (GenomeWeb News) – Illinois-based diagnostics company Abbott has entered into an agreement with Genentech, Roche, and OSI Pharmaceuticals to create a genetic test for determining which lung cancer patients will benefit from erlotinib treatment, the company announced today.
Erlotinib, which goes by the trade name Tarceva, is an oral tablet used to treat locally advanced or metastatic non-small cell lung cancer in patients who have tried chemotherapy unsuccessfully. It targets a cell-surface protein called the epidermal growth factor receptor that is often overexpressed in non-small cell lung cancer.
Abbott intends to apply its fluorescence in situ hybridization technology to develop a test for extra copies of the gene coding for EGFR. To date, the US Food and Drug Administration has not approved any nucleic acid based tests for predicting successful lung cancer treatment, said Abbott.
Financial terms of the agreement were not disclosed.